114
Participants
Start Date
October 8, 2019
Primary Completion Date
October 31, 2024
Study Completion Date
February 28, 2025
Durvalumab (MEDI4736)
"1500 mg, every 4 weeks. CxD1 for each cycle, 1 cycle = 28 days~EXCEPT FOR CYCLE 1 IN ARM C : at C1D8 and cycle 1 = 35 days~c=cycle D= day"
Monalizumab (IPH2201)
"1500 mg, every 4 weeks. CXD1 for each cycle, 1 cycle = 28 days~c=cycle D= day"
Oleclumab (MEDI9447)
"3000 mg every 2 week x 4 doses, followed by 3000 mg every 4 weeks. C1D1, C1D15, C2D1, C2D15 and CXD1 for the orther cycles, 1 cycle = 28 days.~c=cycle D= day"
Ceralasertib (AZD6738)
"240 mg bid in Cycle 1, Days 1-7, followed by 7 days on treatment in each cycle between Days 22 and 28.~CxD22-D28 for each cycle, 1 cycle = 28 days EXCEPT FOR CYCLE 1 : at C1D1,C1D29 and cycle 1 = 35 days~c=cycle D= day"
DOCETAXEL
"75 mg/m2, every 3 weeks. CxD1 for each cycle, 1 cycle = 21 days~c=cycle D= day"
Savolitinib
"600 mg QD~1 cycle = 28 days"
Assistance Publique Hopitaux de Marseille, Marseille
Assistance Publique Hopitaux De Marseille
OTHER